The authors also showed that SRC-3 KO Tregs can be harvested from tamoxifen-treated genetically engineered SRC-3f/f:FOXP3Cre-ERT2/+ mice and then injected into tumor bearing mice, resulting in tumor eradication, thus demonstrating the translational therapeutic potential of this technology. The gene discussed is MAPK3; the disease is neoplasm.